Taltz: A New Potential Biologic Therapy for Ankylosing Spondylitis?
by C.H. Weaver M.D. 8/1/2018
Spine Community News: Taltz (Ixekizumab) is a biologic, anti-Il-17 antibody that is approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis and psoriatic arthritis. Recently published information from a pivotal phase 3 clinical trial suggests Taltz may also be an effective treatment of ankylosing spondylitis.
The COAST-W clinical trial evaluated the effectiveness and safety of Taltz for the treatment of ankylosing spondylitis in difficult-to-treat patients who had failed one or two anti-tumor necrosis factor antibody therpies. In this study ankylosing spondylitis patients received Taltz or a placebo and were compared at 16 weeks from initiation of treatment. Overall 40% of Taltz treated patients experienced significant improvement in symptoms associated with active ankylosing spondylitis, such as morning stiffness and spinal movement.
The announcement comes after the report of positive results of the COAST-V study which showed positive results in a comparison with Humira(adalimumab) and against placebo. This study also used the 40% improvement as an endpoint.
With two positive phase 3 comparative clinical trials, Taltz does show significant effectiveness in the treatment of ankylosing spondylitis. The manufacturer of Taltz plans to apply for approval from the FDA sometime later this year.
Targeting the IL-17 receptor appears to be an effective approach for treating ankylosing spondylitis; Cosentyx is another anti-Il-17 antibody that is effective in the treatment os ankylosing spondylitis and is already approved by the FDA for ankylosing spondylitis, psoriatic arthritis, and psoriasis.